{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:59:05Z","timestamp":1791064745281,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019721","name":"Roche Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Lung cancer is one of the most prevalent cancers and the leading cause of cancer death. Advanced non-small cell lung cancer (aNSCLC) patients frequently harbor mutations that impact their survival outcomes. There are limited data regarding the prognostic and predictive significance of these mutations on survival outcomes in the real-world setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This observational retrospective study analyzed de-identified electronic medical records from the Flatiron Health Clinico-Genomic and FoundationCore\u00ae databases to identify patients with aNSCLC who initiated first-line immune checkpoint inhibitors (ICI; alone or in combination) or chemotherapy under routine care between 2016 and 2021. The primary objectives were to assess the prevalence of non-actionable mutations and to determine their association with overall survival (OS). Real-world progression-free survival (rwPFS) and real-world response (rwR) were investigated as secondary exploratory outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Based on an assessment of 185 non-actionable mutations in 2999 patients, the most prevalent mutations were <jats:italic>TP53<\/jats:italic> (70%), <jats:italic>KRAS<\/jats:italic> (42%), <jats:italic>CDKN2A\/B<\/jats:italic> (31%), and <jats:italic>STK11<\/jats:italic> (21%). <jats:italic>STK11<\/jats:italic>, <jats:italic>KEAP1,<\/jats:italic> and <jats:italic>CDKN2A\/B<\/jats:italic> mutations were significantly associated with lower rwR, shorter rwPFS and OS. <jats:italic>KRAS<\/jats:italic> mutations were clinically associated with shorter rwPFS in CIT-treated patients. Subgroup analysis revealed that fast progressors were significantly more likely to harbor <jats:italic>STK11<\/jats:italic>, <jats:italic>KEAP1,<\/jats:italic> and <jats:italic>CDKN2A\/B<\/jats:italic> mutations. Accordingly, long-term survivors (LTS) showed a significantly lower prevalence of these mutations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results provide evidence on the prognostic value of <jats:italic>STK11<\/jats:italic>, <jats:italic>KEAP1,<\/jats:italic> and <jats:italic>CDKN2A\/B<\/jats:italic> mutations in patients with aNSCLC. Further research is required to better understand the implications of these findings on patient management and future trial design and treatment selection.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12094-023-03362-8","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T16:08:51Z","timestamp":1704557331000},"page":"1384-1394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6315-7919","authenticated-orcid":false,"given":"Mariano","family":"Provencio-Pulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6436-2201","authenticated-orcid":false,"given":"Diego","family":"P\u00e9rez-Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9619-6065","authenticated-orcid":false,"given":"Sara","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1943-9307","authenticated-orcid":false,"given":"Haroon","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8927-9129","authenticated-orcid":false,"given":"Bego\u00f1a Campos","family":"Balea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0506-1366","authenticated-orcid":false,"given":"Delvys","family":"Rodr\u00edguez-Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3583-1889","authenticated-orcid":false,"given":"Marta L\u00f3pez-Brea","family":"Piqueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2013-8678","authenticated-orcid":false,"given":"Navdeep","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3897-6968","authenticated-orcid":false,"given":"Samantha","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8651-949X","authenticated-orcid":false,"given":"Esther","family":"Vilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9255-4783","authenticated-orcid":false,"given":"Pedro","family":"Ruiz-Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3402-1144","authenticated-orcid":false,"given":"Manuel","family":"Cobo-Dols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,6]]},"reference":[{"issue":"3","key":"3362_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"3362_CR2","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >\/= 50. J Clin Oncol. 2021;39(21):2339\u201349.","journal-title":"J Clin Oncol"},{"issue":"18","key":"3362_CR3","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.3390\/cancers13184705","volume":"13","author":"O Rodak","year":"2021","unstructured":"Rodak O, Peris-Diaz MD, Olbromski M, Podhorska-Okolow M, Dziegiel P. Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy. Cancers (Basel). 2021;13(18):4705.","journal-title":"Cancers (Basel)."},{"issue":"6127","key":"3362_CR4","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546\u201358.","journal-title":"Science"},{"issue":"11","key":"3362_CR5","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.3390\/cancers15112917","volume":"15","author":"X Le","year":"2023","unstructured":"Le X, Elamin YY, Zhang J. New actions on actionable mutations in lung cancers. Cancers (Basel). 2023;15(11):2917.","journal-title":"Cancers (Basel)."},{"key":"3362_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2021.05.026","volume":"159","author":"AI Spira","year":"2021","unstructured":"Spira AI, Tu H, Aggarwal S, Hsu H, Carrigan G, Wang X, et al. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease. Lung Cancer. 2021;159:1\u20139.","journal-title":"Lung Cancer"},{"issue":"3","key":"3362_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11523-021-00815-4","volume":"16","author":"L Bazhenova","year":"2021","unstructured":"Bazhenova L, Lokker A, Snider J, Castellanos E, Fisher V, Fellous M, et al. TRK fusion cancer: patient characteristics and survival analysis in the real-world setting. Target Oncol. 2021;16(3):389\u201399.","journal-title":"Target Oncol"},{"issue":"5","key":"3362_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell. 2018;33(5):843-52.e4.","journal-title":"Cancer Cell"},{"issue":"9","key":"3362_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","volume":"19","author":"F Skoulidis","year":"2019","unstructured":"Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19(9):495\u2013509.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3362_CR10","doi-asserted-by":"publisher","first-page":"20059","DOI":"10.1038\/s41598-021-99524-1","volume":"11","author":"SI Gutiontov","year":"2021","unstructured":"Gutiontov SI, Turchan WT, Spurr LF, Rouhani SJ, Chervin CS, Steinhardt G, et al. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021;11(1):20059.","journal-title":"Sci Rep"},{"issue":"10","key":"3362_CR11","doi-asserted-by":"publisher","first-page":"S424","DOI":"10.1016\/j.jtho.2018.08.480","volume":"13","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Shen R, Plodkowski A, Rizvi H, Ni A, Long N, et al. Concurrent mutations in STK11 and KEAP1 is associated with resistance to PD-(L)1 blockade in patients with NSCLC despite high TMB. J Thorac Oncol. 2018;13(10):S424.","journal-title":"J Thorac Oncol"},{"key":"3362_CR12","doi-asserted-by":"crossref","unstructured":"Cho BC, Lopes G, Kowalski DM, Kasahara K, Wu Y-L, Castro G et al. Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC. Presented at: AACR Virtual Annual Meeting I 2020.","DOI":"10.1158\/1538-7445.AM2020-CT084"},{"issue":"3","key":"3362_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000344","volume":"3","author":"JA Pinto","year":"2018","unstructured":"Pinto JA, Vallejos CS, Raez LE, Mas LA, Ruiz R, Torres-Roman JS, et al. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? ESMO Open. 2018;3(3): e000344.","journal-title":"ESMO Open"},{"key":"3362_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.703143","volume":"11","author":"W Zhao","year":"2021","unstructured":"Zhao W, Jiang W, Wang H, He J, Su C, Yu Q. Impact of smoking history on response to immunotherapy in non-small-cell lung cancer: a systematic review and meta-analysis. Front Oncol. 2021;11: 703143.","journal-title":"Front Oncol"},{"issue":"2","key":"3362_CR15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","volume":"24","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Jordan E, Kim HR, Dienstag J, Yu HA, Sanchez-Vega F, et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clin Cancer Res. 2018;24(2):334\u201340.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3362_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000706","volume":"5","author":"S Papillon-Cavanagh","year":"2020","unstructured":"Papillon-Cavanagh S, Doshi P, Dobrin R, Szustakowski J, Walsh AM. STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort. ESMO Open. 2020;5(2): e000706.","journal-title":"ESMO Open."},{"issue":"9","key":"3362_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238358","volume":"15","author":"NJ Shire","year":"2020","unstructured":"Shire NJ, Klein AB, Golozar A, Collins JM, Fraeman KH, Nordstrom BL, et al. STK11 (LKB1) mutations in metastatic NSCLC: prognostic value in the real world. PLoS ONE. 2020;15(9): e0238358.","journal-title":"PLoS ONE"},{"issue":"3","key":"3362_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/JTO.0000000000000391","volume":"10","author":"FC Gleeson","year":"2015","unstructured":"Gleeson FC, Kipp BR, Levy MJ, Voss JS, Campion MB, Minot DM, et al. Somatic STK11 and concomitant STK11\/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases. J Thorac Oncol. 2015;10(3):531\u20134.","journal-title":"J Thorac Oncol"},{"issue":"7511","key":"3362_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543\u201350.","journal-title":"Nature"},{"issue":"1","key":"3362_CR20","doi-asserted-by":"publisher","first-page":"1865670","DOI":"10.1080\/2162402X.2020.1865670","volume":"10","author":"W Nie","year":"2021","unstructured":"Nie W, Gan L, Wang X, Gu K, Qian FF, Hu MJ, et al. Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation. Oncoimmunology. 2021;10(1):1865670.","journal-title":"Oncoimmunology"},{"issue":"20","key":"3362_CR21","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1101\/gad.225680.113","volume":"27","author":"MC Jaramillo","year":"2013","unstructured":"Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013;27(20):2179\u201391.","journal-title":"Genes Dev"},{"issue":"11","key":"3362_CR22","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.jtho.2019.07.003","volume":"14","author":"F Goeman","year":"2019","unstructured":"Goeman F, De Nicola F, Scalera S, Sperati F, Gallo E, Ciuffreda L, et al. Mutations in the KEAP1-NFE2L2 pathway define a molecular subset of rapidly progressing lung adenocarcinoma. J Thorac Oncol. 2019;14(11):1924\u201334.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3362_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/1078-0432.CCR-19-1237","volume":"26","author":"Y Jeong","year":"2020","unstructured":"Jeong Y, Hellyer JA, Stehr H, Hoang NT, Niu X, Das M, et al. Role of KEAP1\/NFE2L2 mutations in the chemotherapeutic response of patients with non-small cell lung cancer. Clin Cancer Res. 2020;26(1):274\u201381.","journal-title":"Clin Cancer Res"},{"issue":"suppl 15","key":"3362_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2019.37.15_suppl.102","volume":"37","author":"F Skoulidis","year":"2019","unstructured":"Skoulidis F, Arbour KC, Hellmann M, Patil PD, Marmarelis ME, Awad MM, et al. Association of STK11\/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. J Clin Oncol. 2019;37(suppl 15):102.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3362_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jtho.2020.11.015","volume":"16","author":"JA Hellyer","year":"2021","unstructured":"Hellyer JA, Padda SK, Diehn M, Wakelee HA. Clinical implications of KEAP1-NFE2L2 mutations in NSCLC. J Thorac Oncol. 2021;16(3):395\u2013403.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"3362_CR26","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8(7):822\u201335.","journal-title":"Cancer Discov"},{"issue":"5","key":"3362_CR27","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","volume":"76","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, et al. STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T cell activity in the lung tumor microenvironment. Cancer Res. 2016;76(5):999\u20131008.","journal-title":"Cancer Res"},{"issue":"1","key":"3362_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/annonc\/mdw436","volume":"28","author":"H Kadara","year":"2017","unstructured":"Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, et al. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol. 2017;28(1):75\u201382.","journal-title":"Ann Oncol"},{"issue":"13","key":"3362_CR29","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1158\/0008-5472.CAN-18-3527","volume":"79","author":"A Galan-Cobo","year":"2019","unstructured":"Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, et al. LKB1 and KEAP1\/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma. Cancer Res. 2019;79(13):3251\u201367.","journal-title":"Cancer Res"},{"issue":"8","key":"3362_CR30","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","volume":"5","author":"F Skoulidis","year":"2015","unstructured":"Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5(8):860\u201377.","journal-title":"Cancer Discov"},{"key":"3362_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.lungcan.2017.08.002","volume":"112","author":"F Facchinetti","year":"2017","unstructured":"Facchinetti F, Bluthgen MV, Tergemina-Clain G, Faivre L, Pignon JP, Planchard D, et al. LKB1\/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. Lung Cancer. 2017;112:62\u20138.","journal-title":"Lung Cancer"},{"issue":"4","key":"3362_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.annonc.2023.01.011","volume":"34","author":"TSK Mok","year":"2023","unstructured":"Mok TSK, Lopes G, Cho BC, Kowalski DM, Kasahara K, Wu YL, et al. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Ann Oncol. 2023;34(4):377\u201388.","journal-title":"Ann Oncol"},{"key":"3362_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","volume":"8","author":"R Zhao","year":"2016","unstructured":"Zhao R, Choi BY, Lee MH, Bode AM, Dong Z. Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in cancer. EBioMedicine. 2016;8:30\u20139.","journal-title":"EBioMedicine"},{"issue":"2","key":"3362_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S1010-7940(02)00749-2","volume":"23","author":"YL Cheng","year":"2003","unstructured":"Cheng YL, Lee SC, Harn HJ, Chen CJ, Chang YC, Chen JC, et al. Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer. Eur J Cardiothorac Surg. 2003;23(2):221\u20138.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"9","key":"3362_CR35","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","volume":"32","author":"M Reck","year":"2021","unstructured":"Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021;32(9):1101\u201310.","journal-title":"Ann Oncol"},{"key":"3362_CR36","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3389\/fonc.2019.00953","volume":"9","author":"H Yang","year":"2019","unstructured":"Yang H, Liang SQ, Schmid RA, Peng RW. New horizons in KRAS-mutant lung cancer: dawn after darkness. Front Oncol. 2019;9:953.","journal-title":"Front Oncol"},{"key":"3362_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100200","volume":"24","author":"RE Goulding","year":"2020","unstructured":"Goulding RE, Chenoweth M, Carter GC, Boye ME, Sheffield KM, John WJ, et al. KRAS mutation as a prognostic factor and predictive factor in advanced\/metastatic non-small cell lung cancer: a systematic literature review and meta-analysis. Cancer Treat Res Commun. 2020;24: 100200.","journal-title":"Cancer Treat Res Commun"},{"issue":"16 suppl","key":"3362_CR38","doi-asserted-by":"publisher","first-page":"9001","DOI":"10.1200\/JCO.2022.40.16_suppl.9001","volume":"40","author":"EC Nakajima","year":"2022","unstructured":"Nakajima EC, Ren Y, Vallejo JJ, Akinboro O, Mishra-Kalyani PS, Larkins EA, et al. Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis. J Clin Oncol. 2022;40(16 suppl):9001.","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03362-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-023-03362-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03362-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T09:22:13Z","timestamp":1716283333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-023-03362-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,6]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["3362"],"URL":"https:\/\/doi.org\/10.1007\/s12094-023-03362-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,6]]},"assertion":[{"value":"5 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MPP: Advisory board (Roche, Merck, BMS, AstraZeneca, Lilly, Pfizer, Bayer, Amgen, Janssen, Takeda), Speaker (Roche, Merck, BMS, Takeda, Sanofi), Research grant (Roche, BMS, Takeda). BCB: Speaker (Roche, Merck, BMS, AstraZeneca, Sanofi), Travel\/accommodation\/expenses (Roche, BMS, Lilly, Pfizer, Boehringer). DRA: Advisory board (Roche, Merck, BMS, AstraZeneca, Pfizer, Boehringer, Takeda), Speaker (Roche, Merck, BMS, AstraZeneca, Boehringer, Takeda), Travel\/accommodation\/expenses (Roche, Merck, BMS, AstraZeneca). MLBP: Advisory board (Roche, Merck, BMS, Takeda), Speaker (Roche, Merck, BMS, AstraZeneca, Pfizer, Takeda). MCD: Advisory board (Roche, BMS, AstraZeneca, Boehringer), Travel\/accommodation\/expenses (Roche, BMS, AstraZeneca). DPP, SO, HH, NPl, SW, EV, and PRG are Roche Farma SA employees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}